Back

IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2023

- 27 June 2023 - 1 mins read

 Aggregated presentation by day and by market

Name of issuer Identification code of issuer (Legal Entity Identifier) Day of transaction Identification code of financial instrument Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares * Market (MIC Code)
IPSEN 549300M6SGDPB4Z94P11 19/06/2023 FR0010259150 1,320 111.29 AQEU
IPSEN 549300M6SGDPB4Z94P11 19/06/2023 FR0010259150 1,083 111.14 CEUX
IPSEN 549300M6SGDPB4Z94P11 19/06/2023 FR0010259150 514 111.15 TQEX
IPSEN 549300M6SGDPB4Z94P11 19/06/2023 FR0010259150 2,783 111.10 XPAR
IPSEN 549300M6SGDPB4Z94P11 20/06/2023 FR0010259150 839 110.00 AQEU
IPSEN 549300M6SGDPB4Z94P11 20/06/2023 FR0010259150 1,881 109.60 CEUX
IPSEN 549300M6SGDPB4Z94P11 20/06/2023 FR0010259150 689 110.30 TQEX
IPSEN 549300M6SGDPB4Z94P11 20/06/2023 FR0010259150 5,791 109.65 XPAR
IPSEN 549300M6SGDPB4Z94P11 21/06/2023 FR0010259150 1,362 108.94 AQEU
IPSEN 549300M6SGDPB4Z94P11 21/06/2023 FR0010259150 1,633 108.57 CEUX
IPSEN 549300M6SGDPB4Z94P11 21/06/2023 FR0010259150 598 109.11 TQEX
IPSEN 549300M6SGDPB4Z94P11 21/06/2023 FR0010259150 5,607 108.55 XPAR
IPSEN 549300M6SGDPB4Z94P11 22/06/2023 FR0010259150 1,348 106.57 AQEU
IPSEN 549300M6SGDPB4Z94P11 22/06/2023 FR0010259150 2,097 106.75 CEUX
IPSEN 549300M6SGDPB4Z94P11 22/06/2023 FR0010259150 743 105.51 TQEX
IPSEN 549300M6SGDPB4Z94P11 22/06/2023 FR0010259150 5,012 106.59 XPAR
IPSEN 549300M6SGDPB4Z94P11 23/06/2023 FR0010259150 1,459 107.58 AQEU
IPSEN 549300M6SGDPB4Z94P11 23/06/2023 FR0010259150 1,556 107.79 CEUX
IPSEN 549300M6SGDPB4Z94P11 23/06/2023 FR0010259150 368 107.82 TQEX
IPSEN 549300M6SGDPB4Z94P11 23/06/2023 FR0010259150 5,817 107.66 XPAR
             
* Two-digit rounding after the decimal   TOTAL 42,500 108.55  

 

 

Attachment

Related Press Releases

Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA  
13 February 2024 14 mins read

Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA  
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
07 December 2023 10 mins read

Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
US FDA approves Ipsen’s Sohonos™ (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva
16 August 2023 12 mins read

US FDA approves Ipsen’s Sohonos™ (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva
IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2023
11 July 2023 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2023
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
10 July 2023 1 mins read

Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen – Half year statement – 2023 06 30
10 July 2023 1 mins read

Ipsen – Half year statement – 2023 06 30
IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2023
04 July 2023 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2023
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease
30 June 2023 10 mins read

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease
Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva
29 June 2023 7 mins read

Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva